Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGF-βRI), is the only known TGF-β pathway inhibitor. In the present study, we investigated the effect of galunisertib ...

GM-CSF stimulates eosinophils to secrete Transforming Growth Factor-Beta 1 (TGF-β1), which promotes collagen expression in α-SMA cells. Inhibition of eosinophil accumulation post-irradiation through ...

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...

Lysophosphatidic acid receptor 1 (LPA1) is a druggable target for treating pulmonary inflammatory diseases. However, the molecular regulation of LPA1 stability, a factor that critically impacts its ...

Patients with advanced chronic kidney disease may benefit from angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use, but the antihypertensive agents may not reduce ...

Compared with healthy individuals with low/normal Lp (a) levels (median, 7 mg/dL [18 nmol/L]; n=13), individuals with elevated Lp (a) levels (median, 87 mg/dL [218 nmol/L]; n=12) demonstrated an ...

Importantly, the release of LPA by excess autotaxin through the LPA receptors induces nuclear factor kappa-light-chain-enhancer (NF-κB) mediated resistance. Hence by inhibiting the TGF-β pathway in ...

BCA101 is a first-in-class, dual-action, bifunctional antibody designed to inhibit the epidermal growth factor receptor (EGFR) and disable transforming growth factor beta (TGF-β) directly at the ...

Furthermore, Apo regulated the TGF-β/Glut9/activin pathway and macrophage programming. In BPH-1 cells, Apo suppressed AR-mediated proliferation and upregulation of TGFB and NOX4 expression by ...

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, et al. Pre-existing antiacetylcholine receptor autoantibodies and b cell lymphopaenia are associated with the development of myositis ...